4672-18-8

Usage

Uses

Used in Pharmaceutical Synthesis:
4-piperidinobutyronitrile is used as a building block for the synthesis of various pharmaceuticals, contributing to the creation of complex molecules with potential therapeutic applications.
Used in Agrochemical Production:
In the agrochemical industry, 4-piperidinobutyronitrile serves as a key intermediate in the development of compounds designed to protect crops and enhance agricultural productivity.
Used in Chemical Research and Development:
4-piperidinobutyronitrile is utilized as a versatile intermediate in the research and development of new chemical compounds, exploring its reactivity and potential applications in various fields.
Used in Drug Development:
Due to its unique structure and properties, 4-piperidinobutyronitrile is studied for its potential use in the development of innovative drugs, targeting a range of therapeutic areas.

InChI:InChI=1/C9H16N2/c10-6-2-5-9-11-7-3-1-4-8-11/h1-5,7-9H2

Upstream product

• 110-89-4 piperidine 
• 628-20-6 4-Chlorobutyronitrile 
• 110-91-8 morpholine 
• 1027379-53-8 cyano acrylate 
• 5332-06-9 4-bromobutanenitrile 
• 17790-82-8 3-cyanopropanoyl chloride 

Downstream Products

• 4672-16-6 4-piperidin-1-ylbutanoic acid 

Relevant academic research and scientific papers

A Novel Parkinson's Disease Drug Candidate with Potent Anti-neuroinflammatory Effects through the Src Signaling Pathway

Numerous drug treatments are available for Parkinson's disease (PD), an age-related neurodegenerative disease, but most cause serious side effects. Therefore, novel therapeutic strategies that halt disease progression and allow for long-term administration are urgently needed. Neuroinflammation critically contributes to the pathogenesis of PD. Here, we report the discovery and optimization of phloroglucinol derivatives, a novel class of anti-neuroinflammatory compounds. Structural modifications of the hit compound 3-methyl-1-(2,4,6-trihydroxyphenyl)butan-1-one produced 43 derivatives, including a preclinical candidate (compound 21), that exhibited potent in vitro anti-neuroinflammatory effects, good blood-brain barrier penetration, and desirable safety margins in mice at a median lethal dose (LD50) >5000 mg/kg. Its in vivo efficacy was demonstrated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)- and MPTP/probenecid (prob)-induced subacute and chronic PD models, respectively, and α-synuclein transgenic mice. Mechanistic studies revealed neuroinflammation inhibition by targeting Src/phosphatase and tensin homologue deleted on chromosome 10 (PTEN)/Akt signaling might be promising. We highlighted the potential usefulness of phloroglucinol derivatives in PD treatment.

Room temperature solvent free aza-Michael reactions over nano-cage mesoporous materials

An efficient highly acidic three dimensional mesoporous aluminosilicate nano-cage material Al-KIT5, exhibited excellent catalytic activity in solvent free room temperature aza-Michael reactions of amines with α,β- unsaturated carbonyl compounds to produce β-amino carbonyl compounds with 100% product selectivity in a short reaction time. The high acidity, 3D pores, and a huge space in the nano-cages materials make them attractive candidate for carrying out important organic reactions. The catalyst provide a simple, easy to handle method, and could be used to solve the problems of corrosion, toxicity, waste production, and a high cost that are being currently encountered by the conventional homogeneous catalysts.

ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS

The present invention provides compounds and compositions, methods of making them, and methods of using them to modulate α7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory system.

ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS

The present invention provides compounds and compositions, methods of making them, and methods of using them to modulate α7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory system.

ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS

The present invention provides compounds and compositions, methods of making them, and methods of using them to modulate α7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory system.

Fluorescent non-imidazole histamine H3 receptor ligands with nanomolar affinities

ω-Piperidinoalkanamine derivatives with fluorescent moieties (2-cyanoisoindol-1-yl, 7-nitrobenzofurazan-4-yl) have been synthesized starting from piperidine in three steps. The compounds display moderate to good histamine hH3 receptor affinities with Ki values ranging from 178 to 11 nM. The new compounds may act as tools for identification and understanding of the binding site on the histamine H3 receptor.

7-oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease

7-Oxabicycloheptane substituted prostaglandin analogs useful in treating thrombotic and vasopastic disease have the structural formula STR1 wherein m is 1, 2 or 3; n is 1, 2, 3 or 4; Z is --(CH2)2 --, --CH=CH-- or STR2 wherein Y is O, a single bond or vinyl, with the proviso that when n is 0, if Z is STR3 then Y cannot be O, and Z is --CH=CH--, n is 1, 2, 3 or 4; and when Y=vinyl, n=0; R is CO2 H, CO2 lower alkyl, CH2 OH, CO2 alkali metal, CONHSOR3, CONHR3a or --CH2 --5-tetrazolyl, X is O, S or NH; and where R1, R2, R3 and R3a are as defined herein.

Anthelmintic 1-(substituted phenyl)-3-alkanimidoyl ureas

The compounds of this invention are novel imidoylureas having anthelmintic activity and imidoylthioureas having antifertility activity. They are prepared by the reaction of appropriate amidines with appropriate isocyanates or isothiocyanates.